Peter Nählstedt
President and CEO.
CEO since August 2021. Member of the management team since 2019. Member of the Board since 2018.
Born 1974.
Peter Nählstedt has extensive experience in developing global growth companies in Life Science. He was appointed to SenzaGens board of directors in 2018 and has during this time also worked operatively in the company with its commercial development. He has in recent years lead several international growth projects in Life Sciences as a consultant and a board professional. His most recent operative assignment was as CEO of Probi AB. His past experiences includes management positions with Trelleborg Marine Systems and GE Healthcare.
Education: MSc in Chemical Engineering and BSc in Business Administration.
Other significant appointments:
Board chairman at Super Synbiotics AB and board director at Bio-works AB.
Shareholding: 58 700 shares and 375 000 warrants.
Marianne Olsson
VP Finance.
Employed 2016. Member of the management team since 2016.
Born 1961.
Marianne Olsson has 25 years of experience from Lund University where she has worked as a department economist, economist and most recently as administrative manager at the Department of Immunotechnology. In addition, Marianne has been a member of the Board of the Faculty of Engineering LTH at Lund University, as well as a member of the management and Department Board at the Department of Immunotechnology.
Education: Certified Financial Manager via FAR.
Other significant appointments:
None.
Shareholding: 114 285 shares and 150 000 warrants.
Anna Chérouvrier Hansson
VP Strategy & Business Development.
Employed 2017. Member of the management team since 2017.
Born 1973.
Anna has extensive experience from marketing, sales and business development from Camurus, Novo Nordisk, Gambro and DuPont among others. In addition, Anna has been a partner at Zitha Consulting, focusing on commercialisation strategy in the pharmaceutical industry and head of Life Science investments at Invest in Skåne.
Education: Master of European Business Administration and Business Law and Bachelor in Business Administration.
Shareholding: 19 153 shares and 130 000 warrants.
Tina Dackemark Lawesson
VP Marketing and Communications.
Employed 2018. Member of the management team since 2019.
Born 1968.
Tina Dackemark Lawesson has long and broad experience from marketing, IR and communication at life science and technology companies in the build-up and growth phase. She has previously held similar positions at INVISIO, CellaVision and Enzymatica among others.
Education: Bachelor of Education (Languages) as well as studies in Journalism.
Other significant appointments:
Board director at Medimi AB.
Shareholding: 3 000 shares and 150 000 warrants.
Andy Forreryd
VP Sales.
Employed 2017. Member of the management team since 2022.
Born 1984.
Andy Forreryd has many years’ experiences working with in vitro assay development, genomics and machine learning. He is a specialist in biomarker discovery, a skilled research communicator and a co-developer of the GARD technology platform
Education: PhD in Immunotechnology and MSc. in Biotechnology Engineering.
Other significant appointments: None.
Shareholding: 500 shares and 40 000 warrants.
Henrik Johansson
Chief Scientist.
Employed 2014. Member of the management team since 2020.
Born 1982.
Henrik Johansson has more than 15 years of experience of research and development within the fields of cell and molecular biology. He is specialized in in vitro assays for predictive immunotoxicology and is a co-developer of the GARD technology platform, which was first described in detail in his doctoral thesis.
Education: PhD in Immunotechnology and MSc. in Biotechnology Engineering.
Other significant appointments:
None.
Shareholding: 526 shares and 10 000 warrants.
Helen Olsson
VP HR.
With the Company since 2020. Member of the management team since 2021.
Born 1965.
Helen Olsson has over 20 years of experience in organization development, change management, and both operational and strategic HR, including as VP HR at BioGaia.
Education: Degree in behavioral science.
Other significant appointments:
None.
Shareholding: 7 500 shares and 100 000 warrants.
Updated June 26, 2024.
